Peptide News

/gsimages/news/navigating-the-challenges-and-regulatory-landscape-of-neoantigen-peptide-cancer-vaccines.jpg

Challenges & Innovations in Neoantigen Peptide Vaccine Production

The Clinical Application of Neoantigens: A Promising Frontier in Cancer Immunotherapy

Up to 2022, more than 60 peptide drugs have been approved by the FDA/EMA to cure diseases such as diabetes, infections, cancer, chronic pain, and so on.

Unlocking the Mystery of cGMP Peptides: Key Considerations for GMP Compliance in Peptide Drug Quality Control

Learn about the therapeutic versatility of synthetic peptides as amyloidogenic agents and hydrogel components and in targeting and helping overcome tumor barriers.

Genentech has developed a pipeline using various high-throughput and functional assays to identify novel shared neoepitope-MHC pair targets for cancer immunotherapies.

Scientists at the Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Belgium, have developed a new approach to inhibit beta-lactamases to boost antibiotic efficacy.

The emergence of bacterial antibiotic resistance against limited therapeutic options is prompting research into the discovery and optimization of alternative therapies such as cyclic antimicrobial peptides.

Scientists at the Tisch Cancer Institute developed an immunotherapy based on intra-tumor administration of Flt3L and the oncolytic Newcastle Disease Virus (NDV) to improve recruiting and activating dendritic cells.